01.30.13
CHINA: Nu Skin Enterprises, Inc. says it has experienced a “record-setting response” to its ageLOC product introductions in the Greater China and South Asia regions, the latest geographies to initiate orders of the company’s ageLOC R2 and ageLOC Galvanic Body Spa and related skin care products.
“On the heels of a record first quarter, we are pleased to report today that the Greater China and South Asia regions have received approximately $150 million of orders for our new ageLOC products,” said Truman Hunt, president and chief executive officer. “The products will be delivered in connection with upcoming regional events taking place in the second and third quarters. These latest, record-breaking introductions are not only a testament to the strength of our exclusive, super-class of ageLOC products, but further demonstration of the high-caliber and talented sales leaders we have in these regions, as well as throughout the world.”
The company began the global rollout of its new ageLOC products in the first quarter in the US, Japan, Korea and Europe. The company’s latest anti-aging products include the ageLOC Galvanic Body Spa, an advanced skin treatment system that is complemented by the new ageLOC Body Shaping Gel and ageLOC Dermatic Effects Body Contouring Lotion; and ageLOCR2, a nutritional supplement system designed to renew and recharge the body (For more on ageLoc Galvanic Body Spa, see “Everything but the Face,”at happi.com).
Since launching the first ageLOC products three years ago, the anti-aging product portfolio has become a tremendous success for Nu Skin, generating sales of well more than $1 billion worldwide.
“Our previous guidance included a net revenue benefit of $60 million from these ageLOC product introductions, which takes into account potential cannibalization of other products sales, as well as order cancellations and product returns,” said Ritch Wood, chief financial officer. “Based upon the orders we have received, we are raising our revenue guidance by $40 million and our earnings guidance by $0.06 earnings per share, bringing our full year guidance to $1.885 to 1.915 billion of revenue, and $2.98 to $3.06 in earnings per share. These orders will be filled and recorded as revenue in both the second and third quarters based on the timing of our fulfillment of the orders,” concluded Wood.
“On the heels of a record first quarter, we are pleased to report today that the Greater China and South Asia regions have received approximately $150 million of orders for our new ageLOC products,” said Truman Hunt, president and chief executive officer. “The products will be delivered in connection with upcoming regional events taking place in the second and third quarters. These latest, record-breaking introductions are not only a testament to the strength of our exclusive, super-class of ageLOC products, but further demonstration of the high-caliber and talented sales leaders we have in these regions, as well as throughout the world.”
The company began the global rollout of its new ageLOC products in the first quarter in the US, Japan, Korea and Europe. The company’s latest anti-aging products include the ageLOC Galvanic Body Spa, an advanced skin treatment system that is complemented by the new ageLOC Body Shaping Gel and ageLOC Dermatic Effects Body Contouring Lotion; and ageLOCR2, a nutritional supplement system designed to renew and recharge the body (For more on ageLoc Galvanic Body Spa, see “Everything but the Face,”at happi.com).
Since launching the first ageLOC products three years ago, the anti-aging product portfolio has become a tremendous success for Nu Skin, generating sales of well more than $1 billion worldwide.
“Our previous guidance included a net revenue benefit of $60 million from these ageLOC product introductions, which takes into account potential cannibalization of other products sales, as well as order cancellations and product returns,” said Ritch Wood, chief financial officer. “Based upon the orders we have received, we are raising our revenue guidance by $40 million and our earnings guidance by $0.06 earnings per share, bringing our full year guidance to $1.885 to 1.915 billion of revenue, and $2.98 to $3.06 in earnings per share. These orders will be filled and recorded as revenue in both the second and third quarters based on the timing of our fulfillment of the orders,” concluded Wood.